UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (NCT02128230), a na phase 2 study. The primary outcome is The Remission Rate for Participants With High-risk Myeloma.

2. Clinical Question

The study’s stated aim was to improve clinical outcomes in the context of earlier Total Therapy trials. Its description proposes that a treatment sequence incorporating carfilzomib-containing combinations could support timely completion of therapy and sustain complete remission. It also gives a rationale involving treatment-related toxicity and recovery phases, and proposes that consolidation might affect the incidence of positive minimal residual disease. These are statements of study rationale and hypotheses, not findings from the posted results.

The primary question is therefore descriptive in the available record: what remission outcome was observed among participants receiving the study regimen? Without a reported remission result, the record cannot answer even that descriptive question. And because the study has no concurrent control group, the design does not provide a direct within-trial comparison of the regimen against another treatment or usual care.

3. Trial Design

This was a Phase II, single-group study sponsored by the University of Arkansas. The registry lists enrollment of 20 participants and identifies multiple myeloma as the condition. Allocation is listed as not applicable, masking as none, and the study model as single group. These design features mean that the record describes one treatment group rather than a blinded, randomized comparison between groups.

The intervention description is a multistage regimen. The listed plan includes induction, optional bridging, a first transplant, inter-therapy, optional bridging, a second transplant, optional bridging, consolidation, and maintenance. The registry also lists myPRS and the named drug and biologic interventions, including MEL-80+CFZ-TD-PACE with peripheral blood stem cells for transplant stages. The treatment labels and sequence are reported as registry descriptions; the record does not provide enough detail to infer how many participants received each component or completed each treatment stage.

The study started on 2014-06-10, and the primary completion date is 2019-02-19. Its status is terminated. The primary outcome timeframe is described as baseline to either death or study completion for each participant, up to approximately 48 months. The endpoint description also states that the study sought to accelerate and sustain complete remission at 2 years from starting therapy. The registry record does not explain the relationship between these two time descriptions in an analysis plan.

Completion and retention are important context for interpreting the record: 19 participants discontinued before study completion, and one completed all study-related activities. The reason for termination, reasons for individual discontinuations, and detailed follow-up available for each participant are not reported in the registry record. The record does not establish whether participants who discontinued continued to contribute endpoint data.

Because the trial is single group, its posted findings cannot establish a treatment contrast against an internal control group. Comparisons to earlier trials are mentioned as context for the study’s objective, but the registry record does not report a prespecified comparative analysis against those trials.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Nineteen (19) subjects discontinued study prior to completion. Only one (1) subject completed all study related activities.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as The Remission Rate for Participants With High-risk Myeloma, measured over from baseline to either death or study completion for each subject (up to approximately 48 months).

The primary endpoint is titled the remission rate for participants with high-risk myeloma, with the unit recorded as participants and the parameter described as a number. The endpoint description identifies complete remission as the clinical state of interest and frames the goal as accelerating and sustaining it at 2 years from the start of therapy. Its recorded timeframe is baseline to either death or study completion for each participant, up to approximately 48 months.

Remission is used as an outcome because it describes the disease response the study aimed to achieve and maintain. A participant count can communicate how many people met the endpoint, while a rate relates that count to the group assessed. The registry record does not report the number meeting the remission definition, the denominator used for a remission rate, the operational criteria for complete remission, or an endpoint estimate. It therefore does not show the observed remission outcome.

The endpoint description also discusses positive minimal residual disease and the possible role of consolidation. That discussion is framed as a study hypothesis; the single listed primary outcome is the remission measure. A separate minimal residual disease result is not reported in the registry record. The distinction matters: the rationale for an endpoint is not itself evidence that the endpoint was achieved, and a stated hypothesis about another measure is not a reported outcome.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a single-group design allow?

A single-group trial follows participants receiving a study regimen and describes outcomes in that group. It can document what happened among participants whose outcomes were recorded. It does not create a concurrent control group, so it cannot directly estimate a between-group treatment contrast. General statistical interpretation should distinguish a descriptive outcome from a causal comparison: an observed remission count, if reported, would describe participants in this study, but alone would not show what would have happened to the same participants under a different treatment.

Here, the registry identifies a single-group model, no masking, and allocation listed as not applicable. These features are consistent with the absence of a randomized comparator in the record. The registry does not report a separate statistical plan that would clarify whether any external or historical comparisons were intended, nor does it report results from such comparisons.

How should a count or rate be read?

The primary outcome is described as a number of participants, with remission rate in its title. A count states how many participants met a defined outcome; a rate places that count in relation to a denominator. To interpret either, readers need the outcome definition, the assessed population, the timing of assessment, and an explanation of how participants without an assessment were handled. Those details are not fully reported in the registry record. In particular, the record does not give a remission count, a rate, or a confidence interval.

A confidence interval is a general statistical tool for expressing uncertainty around an estimate. It describes a range of values compatible with the data and the calculation method under its assumptions; it does not guarantee that the true value falls in the interval, and it does not address systematic problems such as selection bias or missing outcomes. No confidence interval for remission is reported in the registry record.

What does incomplete follow-up mean for interpretation?

The record states that 19 participants discontinued before completion and that one completed all study-related activities. Discontinuation does not automatically mean that all later outcome information is absent, and it does not establish why a participant left the study. Conversely, a study’s total enrollment does not show that every participant contributed to every endpoint. Statistical interpretation depends on the actual analysis population and the availability of endpoint assessments.

Missing outcome data can affect an estimate when the participants with recorded outcomes differ from those without recorded outcomes. This is a general concern: if missingness is related to response, health status, tolerability, or other factors, an estimate based only on observed outcomes may not represent all enrolled participants. The registry record does not report missing-data methods, sensitivity analyses, analysis populations, or participant-level reasons for discontinuation. The potential direction or size of any bias therefore cannot be determined from the record.

How should the planning illustrations be interpreted?

Sample-size illustrations based on an observed effect are planning calculations, not results about participants’ outcomes. The stated assumptions for those illustrations include a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the target effect is expressed as a stated fraction of the observed effect. The trial itself is single group, so a hypothetical equal-allocation comparison is not a description of its design. These calculations should not be read as observed power or as evidence that the study could or could not detect an effect.

In general, a planning calculation asks how much information a hypothetical design would need to detect a specified effect under specified assumptions. Its usefulness depends on the effect chosen, the outcome model, the design, and the assumptions. When the observed effect used as a reference is unstable or not reported in the registry record, the planning illustration cannot replace a transparent account of the trial’s actual endpoint results and analysis.

Why do outcome type and variability matter?

The primary outcome is classified as binary and described as participants with an event, or counts. For a binary outcome, each participant is classified according to whether the defined event occurred. The interpretation of a count or proportion depends on the exact event definition and the group of participants assessed. The registry’s outcome description does not provide a remission result or enough analysis details to evaluate how the endpoint was operationalized.

For outcomes that can vary more than a simple model expects, over-dispersion is a general statistical concern. It means observed variation exceeds what the assumed model allows; if not accounted for, uncertainty estimates may be too small. This is a general concept and is not evidence that over-dispersion occurred in this trial. The registry record does not report a statistical model, a dispersion estimate, or an analysis addressing over-dispersion for the primary endpoint.

More broadly, a reported p-value would address compatibility with a specified statistical null under assumptions, rather than the clinical importance or causal interpretation of a result. A confidence interval would help communicate precision. Neither a primary-outcome p-value nor a remission confidence interval is reported in the registry record. Without those results and the analysis details, no inferential conclusion about the primary endpoint can be drawn from the posted record.

10. Multiplicity, Missing Data and Analysis Populations

The registry record lists one outcome measure and zero analyses. It does not report a statistical analysis plan, a prespecified testing hierarchy, a multiplicity adjustment, or a plan for selecting among outcomes or time points. Multiplicity is a general concern when several outcomes, comparisons, or repeated tests are considered: conducting multiple tests can increase the chance of at least one apparently notable result by chance. An analysis plan can specify how such testing is controlled or interpreted. The record does not indicate what approach, if any, was used.

The primary outcome description refers both to remission at 2 years from starting therapy and to follow-up from baseline until death or study completion, up to approximately 48 months. The record does not explain how these descriptions were reconciled in the analysis, whether the remission status at a particular time was the principal analysis, or how outcomes after discontinuation were treated. The remission result and the statistical methods used to estimate it are not reported in the registry record.

Missing-data handling is also not reported. The record states that 19 participants discontinued before study completion and that one completed all study-related activities. It does not say whether these participants had endpoint assessments, why they discontinued, whether participants were included in an analysis according to enrollment or treatment received, or how unavailable measurements were handled. Analysis populations such as intention-to-treat or per-protocol are not reported in the registry record.

These gaps prevent assessment of whether the reported endpoint, if available elsewhere, reflects all enrolled participants, only participants with an observed assessment, or another defined group. They also prevent evaluating whether missing outcomes could have changed the interpretation. The available information supports describing the study’s intended endpoint and completion experience, but not reconstructing its efficacy analysis.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: neutropenia / grade 3 (20.0%), hospitalization for syncope (5.0%), hospitalization for parainfluenza (5.0%), hospitalization for hematuria (5.0%), hospitalization for k. pneumonia uti (5.0%).

For the study treatment group, the registry reports 20 participants at risk for serious adverse events and 13 affected. It reports 20 participants at risk for other adverse events and 20 affected. The record also lists 4 deaths. These are descriptive counts in this study group; the figures do not provide a comparison with another treatment group.

The serious adverse-event terms listed include Neutropenia / Grade 3, reported as 20.0%, and Hospitalization for Syncope, Hospitalization for Parainfluenza, Hospitalization for Hematuria, Hospitalization for K. Pneumonia UTI, and Hospitalization for Neutropenic Colitis, each reported as 5.0%. These percentages should be read as reported in the registry, not as estimates of comparative risk. The record does not give event timing, duration, recurrence, treatment-stage exposure, or a causal assessment for each event.

Counts of affected participants and event terms are not interchangeable: a participant may experience more than one event. The registry does not report exposure-adjusted rates or a comparator, so these figures cannot establish whether the regimen increased or decreased event risk relative to another approach. They describe adverse events recorded in the study group only.

12. What the Result Does, and Does Not, Mean

The registry record establishes that a Phase II, single-group study of a multistage regimen for high-risk multiple myeloma enrolled 20 participants and was terminated. It states that 19 participants discontinued before completion and that one participant completed all study-related activities. It also describes a primary remission endpoint and lists adverse-event information. These are meaningful details about the design, follow-up, and posted safety data.

The record does not report the primary remission count or rate, an effect estimate, a confidence interval, or a statistical test. It therefore does not establish how many participants achieved complete remission or how precisely remission was estimated. The study’s goal and endpoint description should not be mistaken for an observed result.

Even if a remission result were available, the absence of a concurrent comparator would limit the conclusions that could be drawn about the regimen’s effect. A single-group outcome can describe the experience of participants in the study, but cannot by itself distinguish treatment effects from other factors. The registry’s mention of earlier trials provides context for the stated objective; it is not a reported controlled comparison.

The posted adverse-event counts are also descriptive. They give information about events recorded among study participants, but do not quantify a comparative safety difference. The record does not report enough detail to assess how event occurrence related to treatment exposure or the many stages of the regimen.

Overall, the registry supports a careful account of study design, endpoint intent, participant discontinuation, and reported adverse events. It does not support a conclusion about whether the regimen improved remission outcomes, nor a comparative conclusion about benefits or harms. Those unanswered questions reflect the limits of the results and analysis information reported in the registry record.

13. Why This Trial Matters Statistically

This trial illustrates why design and completion details matter alongside an endpoint’s clinical aim. A remission endpoint may be directly relevant to a study’s objective, but an endpoint description is not an outcome estimate. Without a reported remission count, rate, or uncertainty measure, readers cannot assess what the study observed or how precisely it estimated the result.

The single-group design is also central to statistical interpretation. It can describe the outcomes recorded among participants who received the study regimen, but does not provide an internal comparison that separates a treatment effect from other influences. A stated intention to improve outcomes relative to earlier research does not substitute for a reported comparative analysis. This distinction is important whenever a trial description is ambitious but the design does not include a control group.

Participant completion adds another layer. The record reports 19 discontinuations before completion and one participant completing all study-related activities. Those details do not explain why participants left or whether endpoint data remained available, but they make it especially important to know how the primary analysis defined its population and handled missing assessments. Those details are not reported in the registry record.

The record also offers an example of the difference between safety counts and comparative safety evidence. Serious adverse events and deaths are reported, but without a comparison group or exposure-adjusted analyses, the counts remain descriptive. Good statistical reading means respecting what these figures can say while not extending them to causal or comparative claims.

Finally, planning illustrations should not be confused with trial evidence. Sample-size calculations depend on their assumptions and do not represent the trial’s achieved power. For a single-group study, a hypothetical two-arm calculation is a planning exercise rather than a description of the actual design. Taken together, these points show how registry interpretation depends on aligning the endpoint, design, observed results, and analysis details.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most consequential limitation for interpreting the primary outcome is that the registry record does not report a remission result. It provides no count, rate, confidence interval, or p-value for the primary endpoint. The endpoint description does not specify the operational criteria used to classify complete remission, and the relationship between the stated 2-year objective and the follow-up timeframe of up to approximately 48 months is not explained in an analysis plan.

The study’s single-group design provides no concurrent control group. As a result, the record cannot support an internal estimate of a comparative treatment effect. The study objective mentions earlier Total Therapy trials, but the registry record does not report a formal comparative analysis or explain whether any such comparison was prespecified.

Retention and analysis details are limited. Although the record states that 19 participants discontinued before study completion and one completed all study-related activities, it does not report reasons for discontinuation, treatment exposure by participant, endpoint data availability, or handling of missing outcomes. The analysis population and statistical methods are not reported. These omissions make it impossible to judge how representative any endpoint estimate would be, even if a result were posted elsewhere.

The intervention is a complex sequence with optional bridging stages and multiple listed components. The record does not report how many participants received each stage, whether the planned sequence was completed by participants who discontinued, or how safety events related to exposure. The study is listed as terminated, but the reason for termination is not reported in the registry record.

Finally, registry safety counts are not paired with a concurrent comparator or exposure-adjusted analysis. The available information is insufficient for a comparative safety assessment. Each limitation narrows the scope of conclusions that can be drawn from the posted record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission — NCT02128230.
• Registry record last updated 2021-06-22; status last verified 2021-04.
• Results first posted 2021-06-22.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The record describes a University of Arkansas-sponsored Phase II, single-group study of a multistage regimen for high-risk multiple myeloma. Enrollment was 20, the status is terminated, and the record gives a primary completion date of 2019-02-19. The primary endpoint is the remission rate, with a study objective focused on complete remission at 2 years. Its recorded timeframe extends from baseline to death or study completion, up to approximately 48 months.

The registry reports that 19 participants discontinued before completion and one completed all study-related activities. It lists serious and other adverse-event counts and 4 deaths. However, it does not report the primary remission result, an analysis of that endpoint, the analysis population, or missing-data methods. The single-group design also has no concurrent comparator. The posted record therefore describes the study’s intent and conduct but does not provide an interpretable estimate of its primary remission outcome or a comparative treatment effect.